Simplex Trading
VRDN icon

Simplex Trading’s Viridian Therapeutics VRDN Stock Holding History

Simplex Trading’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$638K Buy
+32,600
New +$968K ﹤0.01% 2990
2025
Q3 		– Sell
-100
Closed -$1K – 10179
2025
Q2 		$1K Sell
100
-12,600
-99% -$171K ﹤0.01% 8461
2025
Q1 		$171K Sell
12,700
-40,600
-76% -$692K ﹤0.01% 4512
2024
Q4 		$1.02M Sell
53,300
-26,200
-33% -$570K ﹤0.01% 2823
2024
Q3 		$1.81M Buy
79,500
+76,600
+2,641% +$1.25M ﹤0.01% 2363
2024
Q2 		$37K Buy
2,900
+1,200
+71% +$16.6K ﹤0.01% 6375
2024
Q1 		$29K Sell
1,700
-1,200
-41% -$23.3K ﹤0.01% 6787
2023
Q4 		$63K Buy
+2,900
New +$45.8K ﹤0.01% 5869
2023
Q3 		– Sell
-61,300
Closed -$1.46M – 9947
2023
Q2 		$1.46M Buy
61,300
+59,300
+2,965% +$1.52M ﹤0.01% 2232
2023
Q1 		$50K Sell
2,000
-23,200
-92% -$744K ﹤0.01% 5936
2022
Q4 		$736K Buy
25,200
+23,600
+1,475% +$544K ﹤0.01% 2778
2022
Q3 		$32K Buy
+1,600
New +$28.8K ﹤0.01% 7002

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Simplex Trading's VRDN Position: Q4 2025 in Review

Simplex Trading sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 2,756 shares — an estimated $75.6K sold.

Simplex Trading first reported a position in VRDN in Q2 2022 and held it in 10 quarters. The position peaked at $556K in Q2 2023. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Simplex Trading reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 2,756 Viridian Therapeutics shares in Q4 2025, an estimated $75.6K.
  • Simplex Trading first reported a position in Viridian Therapeutics in Q2 2022 and held it in 10 quarters.
  • Simplex Trading's Viridian Therapeutics position peaked at $556K in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.